On January 27, 2016, CBSNews featured Board Member and 2000 AFAR Research Grant recipient, David Sinclair, PhD’s comments on what he hopes a breakthrough could mean for the field of aging.
The article focused on The Palo Alto Longevity Prize, an initiative to encourage innovative research towards a clinical breakthrough in the field of aging.
On the initiative, Dr. Sinclair states: "The goal is similar to all medical research which is to make people healthier and keep people alive longer so we can have more productive lives and not be such a burden to society.”
For more information on the promise of pharmacological initiatives in the field of aging, read about the AFAR-supported TAME trial here.
David Sinclair, PhD, is a Professor and Co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School.
